Skip to main content

The synergy of serum SFRP5 levels and the TyG index in predicting coronary artery disease and prognosing major adverse cardiovascular events


Background and aims

Secreted frizzled-related protein 5 (SFRP5) is a member of the SFRP family that is known for its potent anti-inflammatory properties. Nevertheless, little is known regarding the relevance of SFRP5 in coronary artery disease (CAD). The current study examined the correlation between serum levels of SFRP5 and the triglyceride-glucose (TyG) index in patients who underwent coronary angiography (CAG) as a component of cardiovascular assessment and for the purpose of prognosis evaluation.


A total of 310 hospitalized patients were enrolled in this study between May 2021 and March 2022 and were divided into three groups based on their CAG results and SYNTAX (synergy between PCI with TAXUS drug-eluting stent and cardiac surgery) scores: the control group, mild lesion group, and moderate-severe lesion group. Univariate and multivariate analyses were employed to investigate the relationships between changes in patients and clinical variables. To investigate the impact of the TyG index and serum SFRP5 levels on the occurrence of major adverse cardiovascular events (MACEs), Kaplan‒Meier curves were plotted. Serum SFRP5 levels were measured utilizing an enzyme-linked immunosorbent assay (ELISA) kit.


The serum SFRP5 levels significantly decreased with the increasing severity and complexity of CAD, while the TyG index significantly increased (P < 0.001). Moreover, a significant negative correlation was observed between the serum SFRP5 levels and the TyG index (r = -0.312, P < 0.001). SFRP5 exerts a protective role in different groups of patients. The area under the receiver operating characteristic (ROC) curve indicated that an SFRP5 concentration > 115.58 pg/mL was the best predictive value for CAD (OR:0.87, P < 0.001). MACEs were significantly associated with serum SFRP5 levels and the TyG index, as indicated by both univariate and multivariate Cox regression analyses (P < 0.001). Furthermore, Kaplan‒Meier analysis indicated that as the TyG index decreased and SFRP5 levels increased, the occurrence of MACEs decreased (P < 0.001). Patients with a concentration of SFRP5 > 115.58 pg/mL and a TyG index < 8.49 exhibited a better prognosis for avoiding MACEs (P < 0.001).


These results suggest that the collaboration between serum SFRP5 levels and the TyG index holds promise in predicting CAD and its prognosis.


Coronary atherosclerotic disease and its associated complications are substantial contributors to global mortality and disability [1]. Traditional diagnostic modalities for CAD evaluation include invasive techniques such as selective CAG intravascular ultrasound and optical coherence tomography, all of which are invasive and incur significant costs, thereby constraining their clinical utility [1, 2]. Consequently, there is an urgent need for a practical, low-risk, and cost-effective approach for predicting the occurrence and progression of CAD, as well as for assessing the extent of coronary artery lesions, given the pronounced clinical significance of this pursuit. SFRP5 is a member of the secretory glycoprotein SFRP family that is involved in both insulin resistance and inflammation [3]. Remarkably, SFRP5 exhibits cardioprotective properties, making it a promising candidate as an innovative biomarker for prognosticating the progression of cardiovascular disease [4,5,6]. Moreover, the TyG index has gained prominence as a straightforward measure for assessing insulin resistance [7].

This study aims to investigate the correlation between serum SFRP5 levels and the severity of CAD, as well as their synergistic effect with the TyG index. It is postulated that this synergy is attributed to the role of SFRP5 in regulating inflammatory responses and insulin resistance, while the TyG index directly reflects insulin resistance status and lipid health, creating a complementary relationship. This study, for the first time, combines serum SFRP5 levels and the TyG index for predicting CAD severity and prognosis of MACE. The aim is to identify high-risk patients more accurately through this unique approach and provide them with more personalized and precise medical interventions.

Patients and methods

Research population

This study was a single-center observational cohort study involving a total of 310 patients who underwent CAG at the Department of Cardiology, First Affiliated Hospital of Anhui Medical University, between May 2021 and March 2022, following predefined inclusion criteria. Case inclusion criteria: (1) meeting the diagnostic criteria established by the United States College of Cardiology Heart Association in 2020; (2) not recently taking drugs that affect SFRP5 levels, such as metformin, nonsteroidal anti-inflammatory drugs (NSAIDs), and medications used for obesity management; (3) Providing the informed consent agreement to participate and approval from the medical ethics committee. Exclusion criteria: (1) patients with congenital heart disease, severe heart failure, heart valve disease, myocarditis, pericardial diseases and other heart diseases; (2) patients with diseases that affect the test parameters, such as: serious infectious diseases and autoimmune diseases; and (3) patients with severe liver and renal insufficiency and abnormal coagulation function.

This study received approval from the institutional ethics committee at The First Affiliated Hospital of Anhui Medical University, which adhered to the principles outlined in the Declaration of Helsinki. Every patient provided written informed consent to participate, and precautions were implemented to safeguard the confidentiality of their identities.

Data collection

Standard laboratory methods were employed to measure a range of parameters in the clinical laboratory of the First Affiliated Hospital of Anhui Medical University. These parameters included routine blood tests and D-dimer (D-D), fibrinogen (FIB), lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB), glomerular filtration rate (eGFR), uric acid (UA), serum creatinine (Scr), fasting blood glucose (FBG) levels and glycated hemoglobin (HbA1c) levels. Plasma concentrations of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL-cholesterol (n-HDL-C), very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein A-1 (ApoA-1), apolipoprotein B (ApoB), and lipoprotein(a) (Lp(a)) were measured using an automatic biochemistry analyzer (Hitachi 7150, Tokyo, Japan), following the manufacturer’s immunoturbidimetry method guidelines. Fasting venous blood was collected from the study subjects before CAG, and the supernatant was extracted for testing after centrifugation. The supernatant was divided into 2 parts, sub-packaged in EP tubes, and they were stored at -80 °C. An ELISA was utilized to determine the serum levels of SFRP5. The ELISA kit was procured from Shanghai Aibo Biotechnology Company and utilized in strict adherence to the provided reagent instructions. The severity of CAD was evaluated using the results obtained from CAG and SYNTAX scores. From the electronic medical record management system of the First Affiliated Hospital of Anhui Medical University, a range of data, including vital signs, past medical history, smoking and drinking habits, laboratory test results, electrocardiogram data, and other variables were retrieved.

Definition of risk factors

The selection of variables primarily encompasses risk factors for CAD. BMI was determined by applying the following formula: body mass index (BMI) = weight (kg)/height2 (m2). The calculation for pulse pressure was as follows: pulse pressure (mmHg) = systolic blood pressure (SBP) (mmHg) - diastolic blood pressure (DBP) (mmHg). The TyG index was computed using the following formula: Ln [fasting triglycerides (mg/dL) × fasting blood glucose (mg/dL)/2] [8]. Hypertension was determined by meeting one of the following criteria: (1) currently prescribed antihypertensive medication, or (2) three consecutive resting blood pressure measurements showing an SBP ≥ 140 mmHg or a DBP ≥ 90 mmHg. The diagnosis of diabetes mellitus (DM) was established through the application of one of the following criteria: (1) a conclusive diagnosis ascertained by a medical professional, (2) persistent and prolonged use of medications prescribed for diabetes, or (3) meeting predetermined criteria, which include FBG levels ≥ 7.0 mmol/L, 2-hour postprandial blood glucose levels ≥ 11.1 mmol/L, or random blood glucose levels ≥ 11.1 mmol/L, as determined by an oral glucose tolerance test. The calculation of the neutrophil-to-lymphocyte ratio (NLR) involved dividing the neutrophil count (*10^9/L) by the lymphocyte count (*10^9/L). The patient’s medical history related to drinking and smoking was initially obtained from patient-provided information and subsequently confirmed through relevant laboratory examinations.

Angiographic analyses

The SYNTAX score is a risk stratification tool used for evaluating CAD based on the anatomical characteristics of coronary artery lesions. It provides a quantitative assessment of coronary lesion complexity by considering factors such as lesion location, severity, branching patterns, and calcification. This scoring system is essential for comparing treatment outcomes between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in patients with left main CAD or triple-vessel disease (3VD). Depending on the SYNTAX score range, the severity of coronary artery stenosis was categorized as follows: (1) mild lesion: ≤22 points; (2) moderate lesion: 23–32 points; and (3) severe lesion: ≥33 points [9]. The coronary angiograms were independently analyzed by two highly experienced interventional cardiologists, who were blinded to the patients’ clinical data. Subsequently, the average of their assessments was computed.

Statistical analysis

Statistical analysis was carried out using SPSS 26.0 software (IBM Corp, Armonk, NY, USA), and GraphPad Prism 9.0.2 (GraphPad Software, San Diego, CA, USA) was employed for generating graphs and charts. To evaluate the data distribution, the Kolmogorov‒Smirnov test for normality was used. Continuous variables were reported as either means with standard deviations or medians with interquartile ranges, depending on the outcome of the normality test. For continuous variables with a normal distribution, analysis of variance (ANOVA) was performed to examine group differences. In contrast, for nonnormally distributed continuous variables, the Kruskal‒Wallis H test was performed to assess variations between groups. Categorical variables are presented as counts (percentages), and group differences were evaluated using either the chi-squared test or Fisher’s exact test. Spearman’s correlation coefficient was employed to investigate the relationships between individual independent variables and SFRP5. Logistic regression models were employed to assess the association between each index and the severity of the disease. ROC curves were created to evaluate the diagnostic accuracy of each index for CAD. Patients were stratified into two groups based on the best predictive values, which were determined by sensitivity and specificity calculations. Univariate Cox regression analysis was performed to predict MACEs based on different independent variables. The multivariate Cox regression analysis incorporated independent variables related to lipid metabolism. Finally, Kaplan–Meier curves were utilized to illustrate the MACE risk in both the reduced and normal SFRP5 groups.


Qualified health care professionals conducted patient monitoring through either clinical visits or telephone communication. Follow-up was performed until July 23, 2023, with a median follow-up duration of 17 months (interquartile range: 13 to 17). MACEs included cardiac mortality, nonfatal myocardial infarction, target lesion revascularization, rehospitalization for stroke treatment, and episodes of unstable or worsening angina [10].


Baseline clinical characteristics

Patients were categorized into three groups based on their CAG results and SYNTAX scores: a control group (n = 50), a mild lesion group (< 23 points, n = 175) and a moderate-severe lesion group (≥ 23 points, n = 85). Table 1 outlines the baseline clinical characteristics observed within the study population. No significant differences were observed among the groups (P > 0.001) regarding age, sex, BMI, smoking history, drinking history, hypertension, n-HDL-c, VLDL-C, Scr, and eGFR assay results. Lp(a) and UA levels significantly differed only between the control group and the moderate-severe lesion group. D-D levels significantly differed only between the mild group and the moderate-severe lesion group. LDH and CK-MB values differed significantly between the control group and the mild lesion group and between the mild lesion group and the moderate-severe lesion group. The levels of ApoA1 and ApoB were significantly different between the control group and the mild and moderate-severe lesion groups, whereas no significant difference was observed between the mild group and the moderate-severe group. There was a substantial increase in the concentrations of TC, TG, LDL-C, SFRP5, HbA1c and TyG, and this increase was statistically significant across all groups. In contrast, both HDL-C and EF levels were significantly decreased.

Table 1 Baseline clinical characteristics

SFRP5 and TyG index

Table 2 presents the correlation analysis among serum SFRP5 levels, the TyG index, and various variables within the patient cohort. Notably, serum SFRP5 levels were positively correlated with HDL-C. However, they were negatively correlated with TG, LDL-C, and HbA1c levels and SYNTAX scores, all of which were statistically significant (P < 0.001), and negatively correlated with FBG (r=-0.160, P = 0.005). Conversely, the TyG index was positively correlated with LDL-C, TG, FBG, and HbA1c levels and SYNTAX scores and was negatively correlated with HDL-C levels (P < 0.001). Importantly, the analysis revealed a significant inverse relationship between serum SFRP5 levels and the TyG index (r= -0.312, P < 0.001) (Fig. 1).

Table 2 The correlation between serum SFRP5 levels and the TyG index
Fig. 1
figure 1

Scatter diagram showing the correlation between serum SFRP5 levels and the TyG index

Multiple logistic regression analysis of risk factors of CAD

Figure 2 displays the results of multiple logistic regression analysis, examining the association between serum SFRP5 levels and various relevant variables in patients who enrolled in this research. The forest plot presents the results of the multivariate logistic regression model that examined the relationship between serum SFRP5 levels and various other factors. In the analysis, patients with CAD were considered the dependent variable, while SFRP5, TyG index, LDL-C, and HDL-C were considered independent variables. The logistic multivariate regression analysis revealed that the TyG index and LDL-C were independent risk factors for CAD, while SFRP5 and HDL-C were protective factors for CAD after adjusting for other confounding factors (P < 0.05). These findings suggest that an elevated TyG index, along with increased LDL-C levels, is associated with an increased risk of CAD. Conversely, higher levels of SFRP5 and HDL-C are associated with a reduced risk of CAD.

Fig. 2
figure 2

Forest plot of the results of the multivariate logistic regression model exploring the association between plasma SFRP5 levels and other related factors in patients with CHD.

Diagnostic value of serum SFRP5 levels and the TyG index

The diagnostic value of serum SFRP5 levels and the TyG index was illustrated in the ROC curve for the occurrence of CAD. The optimal cutoff value for the serum SFRP5 concentration was determined to be 115.58 pg/mL. At this threshold, the sensitivity, specificity, and AUC for predicting coronary heart disease were 84.6%, 77.6% and 0.87 [95% CI (0.82,0.92), P < 0.001], respectively. Similarly, the optimal cutoff value for the TyG index was determined to be 8.49, with corresponding sensitivity, specificity, and AUC values of 72.3%, 69.4%, and 0.74 [95% CI (0.65,0.83), P < 0.001], respectively. Notably, when both serum SFRP5 levels and the TyG index were considered together, the combination exhibited improved predictive performance, with corresponding sensitivity, specificity, and AUC values of 90.8%, 79.4%, and 0.91 for predicting the occurrence of CAD [95% CI (0.87, 0.95), P < 0.001] (Fig. 3 & Table 3).

Fig. 3
figure 3

Diagnostic value of plasma SFRP5 levels and the TyG index in ROC curve

Table 3 Diagnostic value of serum SFRP5 levels and the TyG index in ROC curve

The SFRP5 levels, TyG index, and MACEs

Table 4 provides the results of the univariate Cox regression analysis, demonstrating the independent roles of variables as predictors for clinical endpoint events. In this analysis, statistically significant independent associations were observed for surgery time, sex, LVD, EF, SFRP5, TyG index, TG, TC, HDL-C, LDL-C, ApoB, Lp(a), FDP, FIB, D-D, LDH, CK-MB, UA, r, BNP, ALT, and AST (P < 0.05). Using the stepwise forward method, the multivariate Cox regression analysis revealed significant associations (Table 5) for SFRP5 (P = 0.01), TyG index (P = 0.001), and LDL-C (P = 0.043). The Kaplan‒Meier analysis, assessing event-free survival, demonstrated a clear trend. As the TyG index increased, the incidence of MACE increased and SFRP5 levels decreased (P < 0.001) (Fig. 4 & Fig. 5). Patients with a concentration of SFRP5 > 115.58 pg/mL and a TyG index < 8.49 exhibit a better prognosis for avoiding MACEs (P < 0.001) (Fig. 6).

Table 4 Univariate Cox regression analysis of MACE
Table 5 Multivariate Cox regression analysis of MACE
Fig. 4
figure 4

Kaplan‒Meier curves for MACEs of SFRP5.

Fig. 5
figure 5

Kaplan‒Meier curves for MACEs of the TyG index

Fig. 6
figure 6

Kaplan‒Meier curves for MACEs among SFRP5 and the TyG index


This study was designed to explore the correlation between serum SFRP5 levels and the TyG index, as well as their collective influence on MACEs in individuals diagnosed with CAD. There were several main findings of this study. (1) Serum SFRP5 levels were significantly negatively correlated with the TyG index. (2) Assessing the combination of both SFRP5 and the TyG index demonstrates superior predictive efficacy for CAD compared to evaluating either marker alone. (3) Adding SFRP5 to the existing risk prediction model could improve MACE prediction in patients with CAD. Hyperlipidemia is widely acknowledged as an independent risk factor for coronary atherosclerosis, contributing to the increased complexity and severity of coronary artery lesions and thereby significantly affecting patient prognosis [11, 12].

SFRP5 is a member of the SFRP family, which is characterized by a cysteine-rich domain (CRD) in the extracellular region, and it is secreted by adipocytes. This domain binds to Wnt proteins and effectively inhibits the transmission of Wnt signals. SFRP5 plays a crucial role as a modulator in various cellular processes, including but not limited to cell proliferation, differentiation, migration, and apoptosis, owing to its inhibitory function [13,14,15]. In obese animal models, a significant reduction in SFRP5 expression levels has been observed, and this deficiency may be strongly associated with insulin resistance and adipose tissue inflammation [16,17,18]. Noriyuki Ouchi et al. discovered that SFRP5-deficient mice exhibit no discernible alterations under a standard diet but exhibit pronounced inflammation in their adipose tissue and systemic metabolic dysfunction when subjected to a high-calorie diet. Conversely, the administration of SFRP5 in mouse models of obesity and diabetes yields contrasting outcomes, enhancing metabolic functionality and mitigating inflammation within adipose tissue [16]. This discovery suggests that SFRP5 within adipose tissue holds promise as a potential therapeutic target for addressing glucose homeostasis abnormalities linked to obesity.

In the present investigation, a trend that contradicts the findings of Lu et al. [19] emerged, as an inverse relationship between SFRP5 levels and both FBG and HbA1c levels was observed. The majority of studies suggest a potential positive association between SFRP5 and insulin sensitivity, promoting more effective cellular responses to insulin and thus contributing to blood glucose regulation [20, 21]. It is essential to acknowledge that there are also studies indicating a positive correlation between SFRP5 and insulin resistance, along with other metabolic abnormalities [19, 22]. These discrepancies underscore the idea that the mechanism through which SFRP5 impacts inflammation and insulin resistance may be influenced by specific medications, individual patient characteristics, and the overall metabolic context. Therefore, further research is needed to further investigate these mechanisms and gain a more comprehensive understanding of the role of SFRP5 in cardiovascular health and metabolic diseases. Recent investigations have also demonstrated that SFRP5 enhances the stability of carotid plaques by reducing proinflammatory cytokine levels in macrophages. These cumulative findings further underscore the potential therapeutic implications of SFRP5 in the management of cardiovascular and systemic diseases [23, 24]. Tong et al. have demonstrated that low SFRP5 levels and high Wnt5a levels are associated with the presence of CAD [25]. However, Du et al. presented a further perspective. They observed that in patients with ST-segment elevation myocardial infarction (STEMI) upon admission, serum SFRP5 levels initially increase and subsequently decline after timely reperfusion therapy. This acute elevation of SFRP5 levels upon admission is associated with early improvement in left ventricular function and is independently correlated with peak cTnI (cardiac troponin I) levels and baseline cardiac function [15]. These findings imply that the initial surge in SFRP5 levels upon admission may be indicative of a stress response, possibly representing the body’s physiological adaptation to myocardial infarction. As reperfusion therapy advances, the subsequent decline in SFRP5 levels may signify enhanced cardiac function and the repair of myocardial injury. This phenomenon suggests a potential role for SFRP5 in predicting or assessing cardiac function recovery throughout the clinical trajectory following myocardial infarction.

This study also incorporated the TyG index. The TyG index has emerged in recent years as a straightforward and practical indicator for assessing insulin resistance (IR) [26]. In the present study, a significant correlation among serum SFRP5 levels, the TyG index, and the severity of coronary stenosis in CAD was observed. Moreover, the outcomes unveil a notable decrease in the SFRP5 concentration in high SYNTAX groups, suggesting that reduced levels of SFRP5 exert a detrimental effect on the pathology of atherosclerosis. The results of the present study show that serum SFRP5 levels are significantly decreased and negatively correlated with the severity of the condition, which aligns with numerous previous studies [27, 28]. These findings suggest that both serum SFRP5 levels and the TyG index could serve as valuable markers for evaluating lipid metabolism and atherosclerosis. Multivariate logistic regression analysis reveals that TyG serves as an independent risk factor for CAD, whereas SFRP5 plays a protective role in this context. The ROC curve analysis also indicated that SFRP5 has a significant predictive value for CAD. In this study, a combined analysis of SFRP5 and the TyG index was used to assess the diagnostic predictive value for CAD patients. There was a notable increase in diagnostic specificity and positive predictive value for CAD (sensitivity at 90.8%, specificity at 79.4%, AUC at 0.91). This underscores the advantage of the combined detection of these two indicators in accurately predicting the occurrence of CAD. Multifactorial Cox regression analysis suggested that SFRP5 and TyG are both predictive factors for MACEs.

Thus, patients who underwent CAG could be categorized into two groups based on their SFRP5 levels, confirming its suitability for both diagnostic and long-term prognostic purposes. After a follow-up period of 17 months, with an interquartile range of 13 to 17 months, Kaplan‒Meier curves were constructed. From the curves, it becomes evident that with the extension of follow-up time, patients with lower serum SFRP5 concentrations and a higher TyG index have a greater risk of developing MACEs. Based on the cutoff values obtained from the ROC curve and the Kaplan‒Meier analysis, patients with SFRP5 concentrations > 115.58 pg/mL and a TyG index < 8.49 have the lowest risk of MACEs. These findings provide substantial evidence for the diagnosis and risk assessment of CAD. As a result, future clinical approaches aimed at managing CAD should thoroughly explore the roles of SFRP5 and the TyG index. Overall, this study underscores the importance of conducting further research to comprehensively grasp the clinical implications of SFRP5 and the TyG index in the context of CAD.

Study strengths and limitations

This study presents novel findings on the correlation between serum SFRP5 levels and the TyG index in patients. It explores the variances in serum SFRP5 levels and the TyG index across different subgroups of CAD while investigating their association with coronary stenosis. The findings propose that the measurement of serum SFRP5 levels and the TyG index holds promise as potential markers to predict the occurrence and progression in patients with CAD, as well as evaluate coronary disease.

Nonetheless, it is crucial to acknowledge the limitations inherent in this clinical study. First, the study adopts a cross-sectional study conducted at a single center, which introduces potential bias. Furthermore, the limited sample size undermines the robustness of the results. Additionally, the absence of longer-term follow-up data on adverse cardiovascular events in CAD patients hampers our ability to conduct long-term prognosis assessments. Moreover, it is crucial to explore the underlying mechanisms of SFRP5 in regulating the progression of coronary heart disease. Comprehensive animal experiments are essential to provide insights into these mechanisms.

Consequently, it is necessary to conduct large-scale, multicenter, prospective studies, along with additional animal experiments, to validate the diagnostic, severity, and prognostic significance of SFRP5 and the TyG index in relation to CAD.


This study has elucidated the critical association between serum SFRP5 levels and the TyG index and their pivotal roles in CAD. Through rigorous analysis, it was demonstrated that while higher levels of serum SFRP5 act as a protective factor, a higher TyG index is associated with an increased risk of CAD. The combined assessment of serum SFRP5 levels and the TyG index has been shown to enhance the predictive accuracy for CAD, surpassing the performance of each biomarker used independently. From a clinical perspective, this integrated approach ensures a more reliable and precise identification of at-risk patients. This facilitates timely and targeted interventions and aids clinicians in stratifying patients based on their risk, leading to a reduction in the incidence of MACEs. Future clinical practices may consider incorporating serum SFRP5 levels and the TyG index as standard elements of CAD risk assessment and management, ensuring that every patient receives the most informed and effective care possible.

Data availability

The datasets analyzed during the current study are not publicly available due to privacy protection but are available from the corresponding author upon reasonable request.



Secreted frizzled-related protein 5

TyG index:

Triglyceride-glucose index


Major adverse cardiovascular events


Coronary artery disease


Coronary arteriography


Synergy between percutaneous coronary intervention with taxus and cardiac surgery


insulin resistance


Analysis of variance


Enzyme-linked immunosorbent assay


Type II diabetes mellitus


Enzyme-linked immunosorbent assay


Receiver operating characteristic


Apolipoprotein A-1


Apolipoprotein B




Serum creatinine


Fasting blood glucose


Glycated hemoglobin




Body mass index


Uric acid


High-density lipoprotein cholesterol


Low-density lipoprotein cholesterol


very low-density lipoprotein cholesterol




Total cholesterol


Lactate dehydrogenase




D-Dimer assay


Creatine kinase-MB


Estimated glomerular filtration rate


Neutrophil-to-lymphocyte ratio


Area under the curve


Odds ratio


Confidence interval


  1. Ralapanawa U, Sivakanesan R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: a narrative review. J Epidemiol Glob Health. 2021;11(2):169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Malakar AKr, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery Disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812–23.

    Article  Google Scholar 

  3. Liu L, Shi Z, Ji X, Zhang W, Luan J, Zahr T, et al. Adipokines, adiposity, and Atherosclerosis. Cell Mol Life Sci. 2022;79(5):272.

    Article  CAS  PubMed  Google Scholar 

  4. Zhang J, Jia L, Yang Y, Xiao A, Lin X. Lipoprotein (a) and Myocardial Infarction: impact on long-term mortality. Lipids Health Dis. 2023;22(1):70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Miyoshi T, Doi M, Usui S, Iwamoto M, Kajiya M, Takeda K, et al. Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery Disease. Atherosclerosis. 2014;233(2):454–9.

    Article  CAS  PubMed  Google Scholar 

  6. Wang D, Zhang Y, Shen C. Research update on the association between SFRP5, an anti-inflammatory adipokine, with obesity, type 2 Diabetes Mellitus and coronary Heart Disease. J Cell Mol Med. 2020;24(5):2730–5.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Navarro-González D, Sánchez-Íñigo L, Pastrana-Delgado J, Fernández-Montero A, Martinez JA. Triglyceride–glucose index (TyG index) in comparison with fasting plasma glucose improved Diabetes prediction in patients with normal fasting glucose: the vascular-metabolic CUN cohort. Prev Med. 2016;86:99–105.

    Article  PubMed  Google Scholar 

  8. Alizargar J, Bai CH, Hsieh NC, Wu SFV. Use of the triglyceride-glucose index (TyG) in Cardiovascular Disease patients. Cardiovasc Diabetol. 2020;19(1):8. s12933-019-0982–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kappetein AP, Dawkins KD, Mohr FW, Morice MC, Mack MJ, Russell ME, et al. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery Disease.Insights from the SYNTAX run-in phase. Eur J Cardiothorac Surg. 2006;29(4):486–91.

    Article  PubMed  Google Scholar 

  10. Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic Cardiovascular Disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis. 2023;82(1):119–29.

    Article  CAS  PubMed  Google Scholar 

  11. Chen H, Chen J, Zhang F, Li Y, Wang R, Zheng Q, et al. Effective management of Atherosclerosis progress and hyperlipidemia with nattokinase: a clinical study with 1,062 participants. Front Cardiovasc Med. 2022;9:964977.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tietge UJF. Hyperlipidemia and Cardiovascular Disease: inflammation, dyslipidemia, and Atherosclerosis. Curr Opin Lipidol. 2014;25(1):94–5.

    Article  CAS  PubMed  Google Scholar 

  13. Zou DP, Chen YM, Zhang LZ, Yuan XH, Zhang YJ, Inggawati A, et al. SFRP5 inhibits melanin synthesis of melanocytes in vitiligo by suppressing the Wnt/β-catenin signaling. Genes Dis. 2021;8(5):677–88.

    Article  CAS  PubMed  Google Scholar 

  14. Van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant wnt signaling in Multiple Myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33(5):1063–75.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Du Y, Zhao Y, Zhu Y, Hu C, Zhang J, Ji Q, et al. High serum secreted frizzled-related protein 5 Levels Associates with early improvement of cardiac function following ST-Segment Elevation Myocardial Infarction treated by primary percutaneous coronary intervention. J Atheroscler Thromb. 2019;26(10):868–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ouchi N, Higuchi A, Ohashi K, Oshima Y, Gokce N, Shibata R, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010;329(5990):454–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ren Y, Zhao H, Yin C, Lan X, Wu L, Du X, et al. Adipokines, Hepatokines and myokines: Focus on their role and molecular mechanisms in adipose tissue inflammation. Front Endocrinol. 2022;13:873699.

    Article  Google Scholar 

  18. Cheng JX, Yu K. New discovered Adipokines Associated with the pathogenesis of obesity and type 2 Diabetes. Diabetes Metab Syndr Obes Targets Ther. 2022;15:2381–9.

    Article  CAS  Google Scholar 

  19. Lu YC, Wang CP, Hsu CC, Chiu CA, Yu TH, Hung WC et al. Circulating secreted frizzled-related protein 5 and wingless-type MMTV integration site family member 5a levels in patients with type 2 Diabetes Mellitus: Sfrp5 and Wnt5a in type 2 Diabetes Mellitus. Diabetes Metab Res Rev. 2013;n/a-n/a.

  20. Hu Z, Deng H, Qu H. Plasma SFRP5 levels are decreased in Chinese subjects with obesity and type 2 Diabetes and negatively correlated with parameters of insulin resistance. Diabetes Res Clin Pract. 2013;99(3):391–5.

    Article  CAS  PubMed  Google Scholar 

  21. Lv C, Jiang Y, Wang H, Chen B. Sfrp5 expression and secretion in adipocytes are up-regulated during differentiation and are negatively correlated with insulin resistance. Cell Biol Int. 2012;36(9):851–5.

    Article  CAS  PubMed  Google Scholar 

  22. Carstensen M, Wiza C, Röhrig K, Fahlbusch P, Roden M, Herder C et al. Effect of Sfrp5 on Cytokine Release and Insulin Action in Primary Human Adipocytes and Skeletal Muscle Cells. Sanchez-Margalet V, editor. PLoS ONE. 2014;9(1):e85906.

  23. Zhao C, Bu X, Wang W, Ma T, Ma H. GEC-derived SFRP5 Inhibits Wnt5a-Induced Macrophage Chemotaxis and Activation. De Re V, editor. PLoS ONE. 2014;9(1):e85058.

  24. Akoumianakis I, Sanna F, Margaritis M, Badi I, Akawi N, Herdman L, et al. Adipose tissue–derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases. Sci Transl Med. 2019;11(510):eaav5055.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tong S, Du Y, Ji Q, Dong R, Cao J, Wang Z, et al. Expression of Sfrp5/Wnt5a in human epicardial adipose tissue and their relationship with coronary artery Disease. Life Sci. 2020;245:117338.

    Article  CAS  PubMed  Google Scholar 

  26. Park K, Ahn CW, Lee SB, Kang S, Nam JS, Lee BK, et al. Elevated TyG index predicts progression of coronary artery calcification. Diabetes Care. 2019;42(8):1569–73.

    Article  CAS  PubMed  Google Scholar 

  27. Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, et al. Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery Disease: a retrospective cohort study. Cardiovasc Diabetol. 2022;21(1):142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Guan H, Zhang J, Luan J, Xu H, Huang Z, Yu Q, et al. Secreted Frizzled Related proteins in Cardiovascular and Metabolic Diseases. Front Endocrinol. 2021;12:712217.

    Article  Google Scholar 

Download references


Not applicable.


This research was supported by the Natural Science Foundation of Anhui Province, China (grant number:2008085MH239).

Author information

Authors and Affiliations



Conceptualization, Lin Jia; Formal analysis, Lin Jia; Funding acquisition, Xianhe Lin; Investigation, Jian Zhang; Methodology, Lin Jia and Shimei Shang; Project administration, Lin Jia; Software, Lin Jia, Shimei Shang and Yu Yang; Supervision, Xianhe Lin; Validation, Jian Zhang; Writing – original draft, Lin Jia; Writing – review & editing, Lin Jia and Yu Yang. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xianhe Lin.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the institution’s ethics committee of The First Affiliated Hospital of Anhui Medical University and complied with the Declaration of Helsinki. All patients provided written informed consent to participate in this study, and we concealed information related to patient identity.

Consent for publication

Included populations agreed to have information published in the journal.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jia, L., Shang, S., Yang, Y. et al. The synergy of serum SFRP5 levels and the TyG index in predicting coronary artery disease and prognosing major adverse cardiovascular events. Lipids Health Dis 22, 194 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: